Oruka Therapeutics (ORKA) Cash from Operations (2010 - 2026)

Oruka Therapeutics' Cash from Operations history runs 17 years deep, the most recent figure standing at 23578000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations fell 12.98% year-over-year to 23578000.0 in Q1 2026; TTM through Mar 2026 was 90919000.0, a 15.76% decrease from a year earlier, with the FY2025 full-year figure at 88210000.0, down 52.51% from the prior year.
• Cash from Operations eased to 23578000.0 in Q1 2026 per ORKA's latest filing, from 22610000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 168000.0 in Q1 2024 and bottomed at 27818000.0 in Q3 2024.
• The 5-year median for Cash from Operations is 4298000.0 (2022), against an average of 10914764.71.
• Across the five-year window, Cash from Operations soared 89.47% in 2024 and sank 12322.02% in 2025, its largest moves.
• Year by year, Cash from Operations stood at 1494000.0 in 2022, then gained by 29.32% to 1056000.0 in 2023, then plunged by 1682.01% to 18818000.0 in 2024, then fell by 20.15% to 22610000.0 in 2025, then declined by 4.28% to 23578000.0 in 2026.
• Per Business Quant, the three latest ORKA Cash from Operations figures stand at 23578000.0 (Q1 2026), 22610000.0 (Q4 2025), and 21586000.0 (Q3 2025).